Palladium Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | $12.1M | Sell |
234,207
-8,516
| -4% | -$442K | 0.53% | 54 |
|
|
2021
Q4 | $14.3M | Sell |
242,723
-1,237
| -0.5% | -$61.3K | 0.59% | 48 |
|
|
2021
Q3 | $10.5M | Sell |
243,960
-4,886
| -2% | -$216K | 0.48% | 58 |
|
|
2021
Q2 | $9.74M | Sell |
248,846
-11,499
| -4% | -$447K | 0.46% | 58 |
|
|
2021
Q1 | $9.43M | Sell |
260,345
-16,986
| -6% | -$603K | 0.47% | 59 |
|
|
2020
Q4 | $10.2M | Sell |
277,331
-30,755
| -10% | -$1.13M | 0.57% | 51 |
|
|
2020
Q3 | $10.7M | Sell |
308,086
-11,593
| -4% | -$406K | 0.68% | 47 |
|
|
2020
Q2 | $9.92M | Sell |
319,679
-8,670
| -3% | -$295K | 0.68% | 47 |
|
|
2020
Q1 | $10.2M | Sell |
328,349
-240,910
| -42% | -$8.21M | 0.85% | 36 |
|
|
2019
Q4 | $21.2M | Sell |
569,259
-77,813
| -12% | -$2.77M | 1.36% | 18 |
|
|
2019
Q3 | $27.1M | Buy |
647,072
+35,282
| +6% | +$1.28M | 1.89% | 12 |
|
|
2019
Q2 | $25.1M | Buy |
611,790
+6,327
| +1% | +$251K | 1.74% | 13 |
|
|
2019
Q1 | $24.4M | Sell |
605,463
-20,969
| -3% | -$840K | 1.76% | 13 |
|
|
2018
Q4 | $25.9M | Sell |
626,432
-22,901
| -4% | -$951K | 2.07% | 11 |
|
|
2018
Q3 | $27.1M | Buy |
649,333
+4,244
| +0.7% | +$163K | 1.85% | 12 |
|
|
2018
Q2 | $22.2M | Sell |
645,089
-2,243
| -0.3% | -$76.7K | 1.61% | 13 |
|
|
2018
Q1 | $21.8M | Sell |
647,332
-9,021
| -1% | -$310K | 1.61% | 13 |
|
|
2017
Q4 | $22.6M | Buy |
656,353
+1,621
| +0.2% | +$55.3K | 1.63% | 14 |
|
|
2017
Q3 | $22.2M | Buy |
654,732
+3,615
| +0.6% | +$116K | 1.69% | 12 |
|
|
2017
Q2 | $20.8M | Buy |
651,117
+12,274
| +2% | +$387K | 1.64% | 16 |
|
|
2017
Q1 | $20.7M | Buy |
638,843
+14,298
| +2% | +$451K | 1.67% | 16 |
|
|
2016
Q4 | $19.2M | Buy |
624,545
+259,611
| +71% | +$7.93M | 1.62% | 18 |
|
|
2016
Q3 | $11.7M | Buy |
364,934
+6,965
| +2% | +$233K | 1.02% | 27 |
|
|
2016
Q2 | $12M | Sell |
357,969
-14,040
| -4% | -$448K | 1.09% | 24 |
|
|
2016
Q1 | $10.5M | Sell |
372,009
-212,950
| -36% | -$6.08M | 0.96% | 34 |
|
|
2015
Q4 | $17.9M | Buy |
584,959
+12,997
| +2% | +$409K | 1.66% | 15 |
|
|
2015
Q3 | $17M | Buy |
571,962
+1,883
| +0.3% | +$60.4K | 1.68% | 13 |
|
|
2015
Q2 | $18.1M | Buy |
570,079
+1,677
| +0.3% | +$54.7K | 1.62% | 13 |
|
|
2015
Q1 | $18.8M | Buy |
568,402
+8,091
| +1% | +$257K | 1.61% | 14 |
|
|
2014
Q4 | $16.6M | Buy |
560,311
+16,937
| +3% | +$486K | 1.44% | 20 |
|
|
2014
Q3 | $15.2M | Buy |
543,374
+5,050
| +0.9% | +$142K | 1.37% | 20 |
|
|
2014
Q2 | $15.2M | Buy |
538,324
+5,413
| +1% | +$154K | 1.35% | 21 |
|
|
2014
Q1 | $16.2M | Buy |
532,911
+10,542
| +2% | +$314K | 1.49% | 16 |
|
|
2013
Q4 | $15.2M | Sell |
522,369
-1,379
| -0.3% | -$40.1K | 1.44% | 15 |
|
|
2013
Q3 | $14.3M | Sell |
523,748
-865
| -0.2% | -$23.5K | 1.45% | 13 |
|
|
2013
Q2 | $13.9M | Buy |
+524,613
| New | +$14.5M | 1.47% | 13 |
|
Other funds holding PFE
Palladium Partners's PFE Position: Q1 2022 in Review
Palladium Partners reduced its Pfizer (PFE) stake by 3.5% in Q1 2022, selling an estimated $442K and leaving 234,207 shares worth $12.1M. The position accounts for 0.53% of the portfolio, ranked #54.
Palladium Partners first reported a position in PFE in Q2 2013 and has held it in 36 quarters since. The position peaked at $27.1M in Q3 2018. 3,196 funds tracked by Wall St. Rank hold PFE as of Q1 2022.
- Palladium Partners held 234,207 shares of Pfizer worth $12.1M as of Q1 2022.
- Palladium Partners sold 8,516 Pfizer shares in Q1 2022, an estimated $442K.
- Pfizer made up 0.53% of Palladium Partners's portfolio in Q1 2022, its #54 holding.
- Palladium Partners first reported a position in Pfizer in Q2 2013 and has held it in 36 quarters since.
- Palladium Partners's Pfizer position peaked at $27.1M in Q3 2018.
- 3,196 funds tracked by Wall St. Rank held Pfizer as of Q1 2022.
Based on Palladium Partners's 13F filing for Q1 2022, filed 26 Apr 2022.